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1 Rheumatology, University Hospitals Coventry & Warwickshire, Coventry, UK Background: Sun exposure is important to maintain adequate levels of vitamin D. This is a challenge for patients with SLE given the majority of patients have photosensitivity. A number of studies have suggested an association between low vitamin D levels and increased disease activity but other studies have not corroborated this. A recent review article has concluded there is no strong evidence to suggest there is improvement in clinical symptoms following supplementation but there are very few data from the UK. There is no consensus on optimal supplementation making management unclear, although most physicians would tend to treat existing vitamin D deficiency. We therefore performed this study to look at our own cohort to investigate the prevalence of vitamin D deficiency and assess what treatment options had been effective at maintaining vitamin D-replete status. Methods: We retrospectively looked at all patients attending the connective tissue disorder clinic at University Hospitals Coventry & Warwickshire from March to August 2014. Only patients with a clinical diagnosis of SLE were included. This study was approved by the local research and development department. We recruited 100 patients obtaining blood results, demographics and prescriptions from our electronic notes system (CRRS). Data were analysed using MS Excel. Results: 100 patients were included, although 16 patients had not had vitamin D levels tested. The demographics are shown below (Table 1) . 84 patients had vitamin D levels tested during their time in clinic. 26 had vitamin D insufficiency (30-50 nmol/l) and 31 had deficiency (<30 nmol/l) with a mean value of 28 nmol/l. 27 patients had normal levels; of these 17 were already on maintenance therapy. This level of low vitamin D is comparable to data collected previously on high risk populations within the hospital trust in 2013. High dose vitamin D treatment with ergocalciferol or cholecalciferol (total dose 400 000 units to 720 000 units) was given to 23 patients, 21 with deficiency and 2 with insufficiency. 18 then continued on a maintenance therapy (Adcal D3, Calcichew D3 or Fultium D3). Of the 34 patients not receiving high dose therapy, 26 were started on maintenance therapy. 8 patients received no treatment. 43 of the 57 patients had a repeat test performed following treatment and for 36 patients, levels had normalized. Of these 36 patients 27 had their level rechecked subsequently and 16 had dropped again below 50 nmol/l. Two of these patients had further high dose treatment with the rest continuing maintenance therapy alone. 
